Lord, Abbett & Co
ALDR

Lord, Abbett & Co’s Alder Biopharmaceuticals ALDR Stock Holding History

Lord, Abbett & Co’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-155,063
Closed -$4.47M – 1013
2015
Q1 		$4.47M Buy
+155,063
New +$4.26M 0.01% 755

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Lord, Abbett & Co's ALDR Position: Q2 2015 in Review

Lord, Abbett & Co sold out of Alder Biopharmaceuticals (ALDR) in Q2 2015, closing a stake of 155,063 shares — an estimated $4.47M sold.

Lord, Abbett & Co first reported a position in ALDR in Q1 2015 and held it in 1 quarter. The position peaked at $4.47M in Q1 2015. 127 funds tracked by Wall St. Rank hold ALDR as of Q2 2015.

  • Lord, Abbett & Co reported no remaining Alder Biopharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Lord, Abbett & Co sold 155,063 Alder Biopharmaceuticals shares in Q2 2015, an estimated $4.47M.
  • Lord, Abbett & Co first reported a position in Alder Biopharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Lord, Abbett & Co's Alder Biopharmaceuticals position peaked at $4.47M in Q1 2015.
  • 127 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2015.

Based on Lord, Abbett & Co's 13F filing for Q2 2015, filed 14 Aug 2015.